secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124546
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q3 revenue $104.8M (+81% YoY); Auvelity $80.4M (+113%); net loss $64.6M
------------------------------------------------------------------------------

- Total net product revenue $104.8M, up 81% YoY; Auvelity $80.4M (+113%), Sunosi $24.4M (+21%).
- Net loss $64.6M ($1.34 loss per share); cash and equivalents $327.3M at Sept 30, 2024.
- Auvelity sales force to expand to ~300 reps in Q1 2025 due to strong demand growth.
- AXS-07 migraine NDA resubmission accepted with PDUFA goal date January 31, 2025.
- Topline results for AXS-05 (AD agitation) and AXS-12 (narcolepsy) on track for Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/0000950170-24-124546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer